Based on the results of two phase II trials by Friedman et al (AVF3708g) [17] and Kreisl at al (National Cancer Institute 06-C-0064E) [18], BEV, a humanized monoclonal antibody against the vascular endothelial growth factor (VEGF), received accelerated approval for recurrent GBM therapy by FDA on May 9, 2009 [19]. The gene discussed is VEGFA; the disease is glioblastoma.